Brexit - the EU FMD's painful problem7 Feb 2019
Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.
Now, after 5 years of preparation and with the compliance deadline only weeks away, the lack of clarity around Brexit remains an obstacle for pharma companies operating on both sides of the Channel.
So, what does Brexit mean for the FMD?
We ask industry leader - Daniel Tedham, Managing Director, Wasdell Manufacturing a division of the Wasdell Group - about the current state of the exit agreement, the possibility and problems of a ‘no deal’ and the impact on the UK and European pharmaceutical industries.
What will be the impact of Brexit on the FMD?
Tedham: “There is still a lot of uncertainty surrounding the impact that Brexit will have on the EU FMD regulations. The date for the UK’s exit from the EU is the 29 March 2019, meaning up until this date the UK will legally need to comply with all EU legislation including the EU FMD.
“The Medicines and Healthcare products Regulatory Agency (MHRA) has recently released guidance which outlines an implementation period between 30 March 2019 and 31 December 2020, during which time the UK pharmaceutical industry would continue to meet all EU FMD requirements while the UK authorities work to develop a system that will work alongside the EU’s.”
What are the implications of a ‘no-deal’ Brexit?
Tedham: “While the UK will still have its own Medicines Verification Systems – the UKMVS – it would also need continued access to the European Medicines Verification System (EMVS) to allow the FMD legislation to be fully effective. In the event of a ‘no-deal’ Brexit this is not guaranteed.
“The logistics of how this will work are not yet fully understood. The political fallout of a hard Brexit could potentially affect patient safety due to reduced access to vital medicines and delays in accessing critical information.”
What are companies doing to ensure operations are unaffected by Brexit?
Tedham: “Many UK-based companies have opted to create contingency plans, establishing a presence in the EU or forming partnerships with third parties to ensure sufficient resource for additional release testing requirements. At Wasdell, we are building a new facility in Dundalk, Ireland to ensure business continuity for our customers. We have also started to develop bespoke alterations to supply chains to ensure minimal impact, regardless of the outcome of Brexit negotiations.”
Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering
27 Jan 2019
New report highlights Germany, France and Switzerland as tier-one nations for ‘drug delivery innovation’, and warns the challenge will be to scale-up and approve promising prototypes.Read more
New API screening program strengthens Particle Sciences' nanomilling offering
22 Jan 2019
Advanced formulation techniques such as nanomilling may provide an excellent route to improved bioavailability and enhanced therapeutic effect.Read more
Univercells introduces breakthrough vaccine manufacturing platform
13 Jan 2019
The automated NevoLine bioproduction system that facilitates safer, faster and closed bioprocessing in a much smaller footprint.Read more
BMS and Celgene merge to create premier innovative biopharma company
3 Jan 2019
Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.Read more
An increased risk of a hard or ‘no deal Brexit?
24 Dec 2018
A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.Read more
One month on: medical cannabis is still taboo despite change in law
11 Dec 2018
Restrictive guidelines have led many to buy CBD products online, leading to a boom in production with many products going to market without sufficient quality control.Read more
EU FMD - time is running out!
13 Nov 2018
Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.Read more
Proprietary nasal delivery formulation of diazepam reaches NDA
7 Nov 2018
The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.Read more
DSCSA one-month countdown!
30 Oct 2018
With only a month to go, it really is too late to start trying to develop an in-house solution.Read more
Global pharma set for strong year
23 Oct 2018
Eight of the top ten pharma nations reporting improving market conditions.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation